Cataract Surgery Devices Market Size and Share

Cataract Surgery Devices Market Summary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Cataract Surgery Devices Market Analysis by Mordor Intelligence

The cataract surgery devices market size is expected to grow from USD 8.90 billion in 2025 to USD 9.28 billion in 2026 and is forecast to reach USD 11.41 billion by 2031 at 4.22% CAGR over 2026-2031. Demand is underpinned by a growing pool of older patients, heightened awareness of sight-restoring surgery, and steady reimbursement in high-income economies. Premium intraocular lenses, femtosecond laser platforms, and artificial-intelligence-aided planning tools are gaining traction as surgeons target faster procedures with fewer visual side effects. At the same time, value-oriented phaco systems and monofocal lenses remain critical in middle-income regions working through large surgical backlogs. Competitive intensity is rising as leading manufacturers pursue portfolio-expansion deals, integrate digital guidance software, and expand training programs to protect share in an increasingly price-sensitive environment.

Key Report Takeaways

  • By product type, intra-ocular lenses held 41.02% of the cataract surgery devices market share in 2025, while femtosecond laser systems are projected to expand at a 6.12% CAGR through 2031.
  • By surgery technique, phaco-based standard surgery led with 34.05% revenue share in 2025; femtosecond-laser-assisted cataract surgery is set to grow the fastest at a 5.73% CAGR to 2031.
  • By end user, hospitals accounted for 42.10% of the cataract surgery devices market size in 2025, whereas ambulatory surgery centers are expected to post a 5.61% CAGR over 2026-2031.
  • By geography, North America dominated with a 38.20% share in 2025; Asia-Pacific is the quickest-rising region with a 6.04% CAGR forecast to 2031.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.

Segment Analysis

By Product Type: Premium IOLs Reshape Value Proposition

In 2025, intra-ocular lenses captured 41.02% of the cataract surgery devices market share, reflecting their indispensable role in every procedure. Penetration of multifocal, toric, and extended-depth-of-focus models pushes average selling prices upward, creating an attractive profit pool for integrated manufacturers. Continuous improvements, such as glistening-free hydrophobic materials and blue-light-filtering chromophores, drive repeat interest among surgeons seeking post-operative satisfaction gains. Femtosecond laser systems, although representing a smaller revenue base, are projected to grow at a 6.12% CAGR to 2031 as evidence mounts that consistent capsulotomies translate into fewer lens dislocations and faster refractive recovery.

Cost-optimized phaco consoles continue to sell well in emerging economies where maintenance support can be inconsistent. Vendors often pair these with reusable handpieces and multi-country training caravans. On the premium end, next-generation phaco pumps with venturi fluidics and real-time occlusion sensing deliver sub-10-second effective phaco time, reducing corneal edema risk in dense nuclei cases.

Cataract Surgery Devices Market: Market Share by Product Type, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Cataract Surgery Devices Market: Market Share by Product Type, 2025

By Surgery Technique: Technology Advances Drive Procedural Evolution

Phaco-based standard surgery retained a 34.05% share in 2025 and remains the benchmark due to decades of familiarity, a robust evidence base, and compatibility with small clear corneal incisions. Surgeons continue to refine parameters such as torsional tip motion and dual-pump fluidics to cut cumulative dissipated energy, thereby reducing endothelial cell loss. The cataract surgery devices market size attributed to phaco systems is predicted to edge up steadily, supported by replacement cycles and emerging-market purchases. FLACS, growing at 5.73% annually, benefits from automated capsulotomies, lens fragmentation patterns, and marketing appeal to tech-savvy patients.

Manual small-incision cataract surgery sustains relevance where surgical volume outstrips capital budgets. Ongoing refinements, including pre-loaded PMMA lenses and foldable insertion sleeves, help standardize outcomes even as costs stay low. Micro-incision techniques and hybrid methods that mix low-energy phaco with manual nucleus removal are being piloted to bridge the gap between affordability and efficiency. Over the forecast horizon, procedural choice will increasingly be tailored to nucleus density, corneal health, and patient payment capacity, keeping all three major techniques alive within the cataract surgery devices market.

By End User: Ambulatory Centers Accelerate Procedure Migration

Hospitals commanded 42.10% of global revenue in 2025, reflecting their ability to manage complex cataracts, uveitis comorbidities, and combined retina cases. Many academic centers also run fellowship programs that influence brand preference among early-career surgeons, cementing a substantial installed base for large-footprint phaco consoles and premium visualization towers. However, ambulatory surgery centers are on track to grow 5.61% per year through 2031, luring payers with lower facility fees and attracting patients who value same-day discharge. In the United States, ASC conversions now exceed 70% for routine cataract cases in certain states, propelling demand for transportable microscopes and compact phaco laser hybrids.

Ophthalmology-dedicated clinics retain importance in Western Europe and parts of Latin America where public systems contract volume to private specialty centers. These sites balance moderate throughput with personalized care, creating a niche for mid-price diagnostics coupled to standard phaco. Across settings, workflow software that integrates biometry, surgical planning, inventory control, and outcome reporting gains favor, highlighting the shift from standalone devices to connected ecosystems within the cataract surgery devices market.

Cataract Surgery Devices Market: Market Share by End User, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Cataract Surgery Devices Market: Market Share by End User, 2025

Geography Analysis

North America remained the largest regional buyer, contributing 38.20% of global revenue in 2025 as advanced reimbursement mechanisms and strong ASC penetration sustain high procedural volumes. The United States tightens its focus on quality metrics; beginning in 2025, updated Medicare rules link facility payment to unplanned return-to-OR rates for “Cataract removal with intraocular lens implantation,” nudging providers to adopt digital planning platforms for error reduction . Canada’s single-payer model, in contrast, emphasizes queue management, reinforcing demand for high-throughput phaco systems coupled with reusable packs.

Asia-Pacific is the fastest-growing region, forecast at 6.04% CAGR through 2031 as demographic pressure meets expanding insurance coverage. China and India are playing a major role in driving growth, due to their huge populations and steadily improving healthcare systems. These countries offer big opportunities, especially as demand rises across different segments. In urban areas and among wealthier groups, there's a growing appetite for premium healthcare services. At the same time, more affordable, value-based solutions are helping meet the needs of the wider population. Japan stands out as a leader in adopting advanced medical technologies, while India is making waves with innovative, cost-effective models that boost surgical efficiency and access..

Europe maintains steady growth, anchored by Germany, France, and the United Kingdom. Day-case surgery overtook inpatient cataract procedures in most EU-27 members by 2024. Eastern Europe shows catch-up potential as EU structural funds subsidize diagnostic and surgical equipment upgrades. South America and the Middle East and Africa deliver smaller volumes but above-average growth as public-private partnerships build new eye hospitals.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Regulatory Landscape

Cataract surgery devices fall under medical-device regulation with risk-based pathways that differ by product type, spanning intraocular lenses (IOLs), phaco platforms, and laser systems. In the United States, the FDA governs clearance decisions for many cataract components via 510(k), while the Quality Management System Regulation (QMSR) updates take effect in February 2026 to align 21 CFR Part 820 with ISO 13485:2016 and tighten quality-system documentation requirements across global supply chains.

Competitive Landscape

The top five manufacturers—Alcon, Johnson & Johnson Vision, Carl Zeiss Meditec, Bausch + Lomb, and NIDEK—control a sizeable portion of global device and consumable sales, reflecting high regulatory barriers and entrenched distribution. Alcon’s 2025 acquisition of Lensar for USD 430 million adds the ALLY dual-pulsed laser platform, granting a robotics-ready system that cuts procedure time and secures service revenues. Johnson & Johnson Vision extends its TECNIS lens family with the Odyssey model, reinforcing a premium IOL pipeline that competes head-to-head with Alcon’s AcrySof IQ Vivity. Carl Zeiss Meditec leverages its VISUMAX SMILE refractive heritage to cross-sell microscopes and digital connectivity solutions that track outcomes across cataract and corneal procedures.

Mid-tier Asian players focus on cost-effective phaco pumps and locally produced hydrophilic lenses, challenging global brands in tenders across South Asia and Africa. Start-ups explore AI-driven planning algorithms, handheld disruptive diagnostics, and modular laser heads that retrofit existing microscopes. Collaborative research with university hospitals on low-energy fragmentation and heads-up 3D visualization indicates a blurring of boundaries between device, software, and educational service segments.

White-space opportunities lie in hybrid phaco-laser units sized for ASC procedure rooms, low-cost aberrometers that feed data into cloud planning suites, and biodegradable viscoelastics. Companies able to integrate these elements into cohesive solutions may accelerate adoption in both high-volume public programs and premium boutique clinics. Overall, the cataract surgery devices market continues to transition from hardware-centric competition to ecosystem-driven differentiation.

Cataract Surgery Devices Industry Leaders

  1. Alcon, Inc.

  2. Bausch & Lomb, Inc.

  3. Johnson & Johnson

  4. Carl Zeiss Meditec AG

  5. NIDEK CO., LTD.

  6. *Disclaimer: Major Players sorted in no particular order
Cataract Surgery Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Market Opportunities and Future Outlook

Premium IOL design and refractive precision remain the clearest route to higher-value procedure segments. Recent product activity also points to where upgrades are concentrating, with the US FDA approval of the TECNIS PureSee IOL in March 2026, ZEISS Medical Technology beginning six-country implantations of the AT LUCIA toric 721P IOL in June 2026, and Alcon and RxSight announcing a non-exclusive collaboration in July 2026 to develop adjustable presbyopia-correcting IOLs.

Recent Industry Developments

  • July 2026: Bausch + Lomb announced the US launch of the EyeGility Inserter, a preloaded IOL delivery system for the enVista IOL family. The system targets more consistent implantation steps and reduced handling in high-throughput cataract settings, strengthening Bausch + Lomb's procedural workflow position alongside its enVista lens franchise.
  • December 2025: The European Commission proposed amendments to MDR/IVDR compliance via COM(2025) 1023, aiming to simplify elements of MDR/IVDR conformity assessment and timelines. This proposal could influence market access dynamics for premium IOLs and related capital equipment across Europe.
  • June 2024: Alcon received US FDA 510(k) clearance for the UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS). The clearances advanced Alcon's integrated platform strategy across cataract and vitreoretinal workflows.

Table of Contents for Cataract Surgery Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Cataract Prevalence & Ageing Population
    • 4.2.2 Technological Leaps in Premium IOLs and FLACS
    • 4.2.3 Burgeoning Demand for Day-Care / ASC Cataract Procedures
    • 4.2.4 Emerging Reimbursement in Middle-Income APAC Markets
    • 4.2.5 Increase in Government Efforts to Address Visual Impairment
  • 4.3 Market Restraints
    • 4.3.1 High Capital Cost of Femtosecond Laser Systems
    • 4.3.2 Shortage of Trained Cataract Surgeons in Developing Countries
    • 4.3.3 Increasing Competition From Low-Cost IOL Manufacturers
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product Type
    • 5.1.1 Intra-ocular Lenses (IOL)
    • 5.1.2 Phacoemulsification Systems
    • 5.1.2.1 Standard Phaco Machines
    • 5.1.2.2 Advanced Phaco Machines
    • 5.1.3 Ophthalmic Viscoelastic Devices
    • 5.1.4 Femtosecond Laser Systems
    • 5.1.5 Others (Knives and Low-Cost Consumables)
  • 5.2 By Surgery Technique
    • 5.2.1 Manual Small-Incision Cataract Surgery
    • 5.2.2 Phaco-based Standard Surgery
    • 5.2.3 Femtosecond-Laser-Assisted Cataract Surgery (FLACS)
    • 5.2.4 Others (Extracapsular Cataract Extraction, Intracapsular Cataract Extraction, and Micro-Incision Cataract Surgery)
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ophthalmology Clinics
    • 5.3.3 Ambulatory Surgery Centers
    • 5.3.4 Academic and Research Institutes
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Alcon Inc.
    • 6.3.2 Johnson & Johnson Services, Inc.
    • 6.3.3 Carl Zeiss Meditec AG
    • 6.3.4 Bausch + Lomb
    • 6.3.5 NIDEK CO., LTD.
    • 6.3.6 STAAR SURGICAL COMPANY
    • 6.3.7 HOYA Corporation
    • 6.3.8 EssilorLuxottica
    • 6.3.9 Ziemer Ophthalmic Systems AG
    • 6.3.10 Haag-Streit Group
    • 6.3.11 TOPCON CORPORATION
    • 6.3.12 Glaukos Corporation
    • 6.3.13 HumanOptics Holding AG
    • 6.3.14 Coburn Technologies, Inc.
    • 6.3.15 Iridex Corporation
    • 6.3.16 BVI Medical
    • 6.3.17 Rayner Group
    • 6.3.18 RxSight, Inc.
    • 6.3.19 LensGen, Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment

Research Methodology Framework and Report Scope

Market Definition and Coverage

This market covers the annual revenues generated from devices used to remove a cataract and restore vision, including surgical systems, implantables, and procedure-level consumables sold into hospitals, ambulatory centers, and eye clinics across major regions.

Scope exclusions: We exclude diagnostic imaging equipment, stand-alone refractive lasers not used for cataract removal, and postoperative drug therapies.

Segmentation Overview

  • By Product Type
    • Intra-ocular Lenses (IOL)
    • Phacoemulsification Systems
      • Standard Phaco Machines
      • Advanced Phaco Machines
    • Ophthalmic Viscoelastic Devices
    • Femtosecond Laser Systems
    • Others (Knives and Low-Cost Consumables)
  • By Surgery Technique
    • Manual Small-Incision Cataract Surgery
    • Phaco-based Standard Surgery
    • Femtosecond-Laser-Assisted Cataract Surgery (FLACS)
    • Others (Extracapsular Cataract Extraction, Intracapsular Cataract Extraction, and Micro-Incision Cataract Surgery)
  • By End User
    • Hospitals
    • Ophthalmology Clinics
    • Ambulatory Surgery Centers
    • Academic and Research Institutes
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Data Sources, Market Sizing, and Validation

Desk Research

Desk work starts by grounding the model in procedure reality, since cataract device demand is closely tied to surgery volumes and how sites of care purchase implants and packs. We reviewed public sources such as the World Health Organization, OECD health statistics, national health ministries, and national statistical agencies for aging-population and healthcare-utilization signals that shape cataract backlogs and throughput.

We also checked clinical and utilization context from peer-reviewed ophthalmology journals and open publications from professional bodies (such as ophthalmology societies) to understand practice patterns, including phaco adoption, premium IOL penetration, and the role of femtosecond assistance. To keep the commercial view consistent, we relied on annual reports, investor presentations, product documentation, and reputable news coverage, and we selectively used a paid company-financials and news subscription plus a patent database to confirm product cycles and capacity expansion signals. These examples are illustrative only, and we also used other public and paid sources for data collection, validation, and clarification during the study.

Primary Interviews and Surveys

Primary work focused on confirming what drives actual device revenue in the field, including typical replacement cycles for capital equipment, tendering and distributor markups, and how IOL mix shifts by payer and surgeon preference. We spoke with a balanced set of stakeholders, including hospital procurement staff, ambulatory center administrators, ophthalmic surgeons, service engineers, and distributor-side leaders across APAC, EMEA, and the Americas. Where desk inputs did not align with on-the-ground pricing and utilization, we refined assumptions accordingly.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 26% CXOs: 13%APAC: 42%
Mid tier: 60% Functional/Unit leaders: 37%EMEA: 31%
Smaller Players: 14% Managers: 50%Americas: 27%

Market-Sizing & Forecasting

Market sizing is built by reconstructing the demand pool from cataract procedure volumes and then translating that into device revenue using realistic usage and pricing assumptions for the main device groups. Where a country has limited published procedure counts, we estimate volume using age-cohort expansion, surgical coverage indicators, and capacity constraints. The model is then adjusted once primary feedback confirms feasible throughput.

Key inputs include cataract surgery rates per 100,000 population, the share of procedures done in ambulatory settings, IOL mix (standard versus premium), average device replacement cycles for phaco and laser platforms, and typical price bands by region after distributor and tender effects. Results are corroborated with selective bottom-up approximations, such as sampled average selling price times estimated unit demand for IOLs and consumables, plus channel checks on capital placements, which helps handle gaps without implying a complete supplier roll-up.

Forecasting relies mainly on scenario analysis tied to a small set of drivers that can be tracked each year, including population aging, backlog clearance pace, reimbursement changes, and premium IOL adoption. We also apply smoothing on historical procedure trends where reliable time series exist. The final growth path is aligned to expert consensus from interviews before the yearly values are locked.

Data Validation & Update Cycle

Validation is done through multiple checks so the totals do not rely on any single source or assumption. We compare outputs against independent signals such as reported cataract procedure volumes, installed base commentary for key surgical platforms, and regional price benchmarks. Any large variances are reviewed and reworked until the drivers explain the outcome.

Before sign-off, the model goes through an analyst review sequence that checks for outliers in growth rates, abrupt ASP changes, and unrealistic shifts in setting-of-care shares. When a material mismatch appears, targeted re-contacts are triggered with interviewees to confirm whether it reflects a temporary disruption or a true demand change. Reports are refreshed annually, with interim updates when notable events affect procedure flow, pricing, or reimbursement, and a final pre-delivery pass is completed so the numbers reflect the latest available evidence.

Mordor Intelligence's Cataract Surgery Devices Market Size Compared Against Other Published Estimates

Published market numbers for cataract surgery devices can vary even when they appear to cover the same topic. The main drivers are differences in the counted device basket and the revenue capture point. Timing also matters, since some estimates anchor to an older base year and then extend forward using a single growth rate.

By tracking procedure-linked demand drivers and refreshing implant and consumable pricing assumptions each year, Mordor Intelligence keeps the total tied to first-sale device revenue and avoids mixing in adjacent eye-care items that are not used in cataract removal.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
Mordor Intelligence USD 9.28 B (2026)
Industry Data Publisher A USD 9.18 B (2026)Uses a faster long-range CAGR and offers limited clarity on whether values are first-sale revenues versus mixed channel prices, which can compress the near-year size but expand later years.
Press Syndicate B USD 9.25 B (2025)Anchors to a different base year and provides fewer details on device-basket boundaries (for example, how capital systems versus procedure packs are counted), which can shift totals when converted to a single current-year view.

The spread in the table is mostly explained by year anchoring and what gets counted as cataract-only device revenue versus broader ophthalmic equipment and channel-priced sales. Using a repeatable procedure-to-revenue logic, with clear inclusion rules and practical checks from interviews, helps keep the estimate stable and easier to reconcile across regions and device categories.

Key Questions Answered in the Report

What is the current value of the cataract surgery devices market?

The cataract surgery devices market size is USD 9.28 billion in 2026.

How fast is the market expected to grow over the next five years?

It is projected to expand at a 4.22% CAGR, reaching USD 11.41 billion by 2031.

Which product category holds the largest revenue share?

Intra-ocular lenses command 41.02% of revenue, led by rising adoption of premium multifocal and toric models.

Why are ambulatory surgery centers gaining prominence?

ASCs provide cataract procedures at lower facility costs and enable same-day discharge, driving a 5.61% CAGR in device spending through 2031.

Which region offers the highest growth potential?

Asia-Pacific is forecast to post a 6.04% CAGR as China and India expand reimbursement and address surgical backlogs.

What technological trend will shape premium procedures?

Wider use of femtosecond-laser-assisted cataract surgery, combined with advanced intraocular lenses and AI-guided planning, is set to enhance precision and patient satisfaction.

Page last updated on:

Cataract Surgery Devices Report Snapshots